EXAI - Exscientia gains as enrollments begin for cancer trial

2023-07-10 12:43:50 ET

The ADRs of Exscientia plc ( NASDAQ: EXAI ) traded higher on Monday after the U.K.-based biotech and its Chinese partner GT Apeiron announced the enrollment of the first patient in their Phase 1/2 trial for an experimental cancer therapy called GTAEXS617.

The trial, named GTAEXS617-001, is designed to evaluate the oral CDK7 inhibitor in advanced solid tumors as a single agent and in combination with standard of care as a late-line option.

The multi-center, open-label trial will involve patients with solid tumors such as head and neck, colorectal, and pancreatic cancer who have failed standard of care.

GTAEXS617-001 comprises two stages: a dose escalation portion designed to evaluate up to seven dose levels to find the recommended Phase 2 dose, and a dose expansion phase that will commence once the RP2D is identified. The investigators have selected the objective response rate as the primary efficacy goal of the dose escalation phase.

More on Exscientia

• Exscientia's AI-Powered Drug Discovery Platform Is The Future Of Precision Medicine
• Exscientia: Direct Exposure To AI Integration To Drug Discovery, Development

For further details see: